Cannabis Market Research: Methods, Compliance, and Vendors

Cannabis market research requires a mix of primary expert interviews and secondary data platforms to produce insights that are actually useful for investment decisions. Secondary reports lag regulatory shifts by months. Traditional expert networks charge six-figure retainers. If you're a PE/VC associate, strategy analyst, or consultant doing cannabis due diligence, you need a faster, cheaper path to reliable primary data.

Finally, Cannabis Market Research Built for Investment Teams

Most cannabis investors still rely on syndicated reports that were outdated before they hit the inbox. The global cannabis market size is projected to reach USD 86.6 billion by 2031, and the U.S. cannabis market is projected to reach $428.22 billion by 2032. Those headline numbers are everywhere. What's not everywhere: how the DEA's April 2026 rescheduling of medical marijuana to Schedule III changes your target's tax exposure, or how a state licensing cap shift will block your portfolio company's expansion, or how investors should separate medical use from recreational use when interpreting those projections.

Public reports miss these shifts. By the time a syndicated data provider publishes updated figures, the regulatory environment has already moved. Cannabis data tracking faces fragmentation due to differing revenue tracking methods across states, making national-level secondary data unreliable for granular investment decisions.

Traditional expert networks like GLG, AlphaSights, and Third Bridge can connect you with cannabis industry insiders, but they require annual retainers that start well above $150K. That pricing model locks out most mid-market PE/VC teams, boutique consultants, and operators doing pre-fundraise validation.

FieldSignal delivers cannabis market research through pay-per-use expert interviews with former compliance officers, state regulators, dispensary operators, executives from leading cannabis brands, and executives from companies like Curaleaf, Trulieve, and Green Thumb Industries. No annual commitment. No minimum spend. Transparent, pass-through expert fees.

This model works for PE/VC teams evaluating cannabis investments, corporate strategy analysts exploring market entry, consultants building cannabis market assessments, and founders validating expansion opportunities.

Why Cannabis Market Research Works

Effective cannabis market research isn't a generic market study with a plant leaf on the cover. It needs to account for how the cannabis plant sits at the center of highly regulated product categories. The cannabis industry operates under a patchwork of state-level and international laws that changes quarterly. Medical marijuana is legal in 42 U.S. states as of 2025, while 24 U.S. states have legalized adult-use cannabis as of January 2026. Each jurisdiction has different reporting, licensing, and compliance requirements.

Here's what makes purpose-built cannabis research different:

• Real-time regulatory intelligence. Former compliance officers and state regulators reveal enforcement timelines, auditor expectations, and penalties for non-compliance before that information appears in any published report. The DEA reclassified medical marijuana to Schedule III on April 22, 2026, and operators had a 60-day window to submit registration. Ongoing public health debates and concerns about drug abuse still shape how regulators scrutinize the category. That kind of deadline doesn't wait for quarterly reports.

• Consumer behavior data from operators. Dispensary managers and brand executives provide early signals on demand shifts. Consumer demand is shifting from traditional raw flower to value-added products like edibles and vapes. In 2025, flowers/buds accounted for 42.5% of cannabis market share, but beverages are the fastest-growing cannabis product type at 14.6% CAGR. Cannabis beverage sales grew by 15% in Q1 2025 compared to Q1 2024. Younger consumers are helping accelerate demand in these newer formats. You won't find that granularity in a $4,000 syndicated report.

• Market sizing validation. Cultivation directors and supply chain executives validate acres under cultivation, yield per gram, wholesale cost structures, and local regulatory overhead. The cannabis industry is expected to add approximately $149 billion to the economy in 2026. But market size means nothing without understanding the competitive landscape. The top five cannabis operators held only 12.97% of global revenue in 2025, and the cannabis market is highly fragmented with local competition dominating.

• Competitive intelligence from insiders. Former employees at major multi-state operators provide intelligence on expansion plans, compliance infrastructure investments, and positioning for federal law shifts. The number of active cannabis business licenses has dropped by 13% over two years, which signals consolidation that secondary data alone won't explain.

• No annual commitments. Unlike traditional expert networks that require six-figure retainers and minimum spend commitments, FieldSignal operates on a pay-per-use model with pass-through expert fees.

How Cannabis Market Research Works

Step 1: Define Your Cannabis Research Scope

Start with your specific question. Are you evaluating a medical cannabis operator for acquisition? Assessing market entry into a state's recreational market, with state rules governing medical and recreational use in mind? Validating pricing assumptions for cannabis products in a specific category?

You choose between secondary data analysis, primary expert interviews, or a combined approach. Secondary data from platforms like BDSA's GreenEdge or Headset delivers POS-level retail sales data. Primary interviews with industry insiders capture regulatory risk, consumer preferences, and competitive positioning that data platforms can't.

Scope decisions should also account for whether a market was shaped by legalized cannabis through a specific statute; for example, New Mexico's Cannabis Regulation Act was enacted in June 2021.

Set your timeline and budget. Secondary data can produce usable results in one to two days. Primary interview projects typically take three to ten business days depending on scope.

Step 2: Access Cannabis Industry Insiders

Connect with the people who actually know what's happening:

1. Former executives from major operators like Curaleaf, Trulieve, Green Thumb Industries, Canopy Growth Corporation, Aurora Cannabis, and VIVO Cannabis.

2. State regulators and licensing officials who understand upcoming policy changes.

3. Compliance officers who've filed DEA registrations under the new Schedule III framework.

4. Cultivation directors who can validate yield, cost, and supply chain assumptions.

5. Retail managers who see consumer behavior shifts in real time.

Interviews may also include leaders supporting European distribution when diligence involves cross-border growth.

All experts go through compliance vetting. Interview protocols respect confidentiality requirements and insider trading regulations. This isn't a marketplace where you're on your own for legal risk.

Step 3: Analyze Cannabis Market Intelligence

You receive transcripts and actionable summaries within five business days of completed interviews. Findings are validated against regulatory filings, public market data, and state reports.

Apply the intelligence directly to investment decisions, market entry strategies, or competitive positioning across the forecast period. Cross-check expert statements against data from syndicated providers like New Frontier Data or LeafLink's wholesale pricing guides. Analysts can also compare interview findings against estimates of cannabis use to pressure-test demand assumptions.

No guesswork. No stale data. Structured intelligence you can act on.

What Makes Cannabis Research Different

Cannabis market research isn't like researching SaaS or consumer packaged goods. Three structural factors make it fundamentally harder.

Regulatory complexity demands insider knowledge. The global cannabis market is transitioning to a more mature and regulated industry by mid-2026, but the path is anything but smooth, and many reports blur the line between regulated cannabis products and industrial hemp, which can distort diligence. The April 2026 rescheduling only covers state-licensed medical marijuana and FDA-approved cannabis products. Adult use cannabis remains Schedule I. Meanwhile, H.R. 5371 redefines hemp starting November 12, 2026, measuring total THC (including Delta-8 and THCA) and capping container limits at 0.4 mg. Industry analysts estimate 95% of current intoxicating hemp-derived products will become non-compliant. No secondary report published today captures the full operational impact.

State-by-state fragmentation creates data gaps. Massachusetts passed legislation loosening vertical integration requirements and increasing purchase limits in 2026. Texas banned smokable hemp and raised fees massively for consumable hemp product businesses. Ohio banned certain hemp products. New Jersey regulated them differently. These shifts affect cannabis-related businesses differently depending on licensing model and local banking access. Only local operators and regulators understand how these changes play out on the ground. Cannabis regulation is influenced by a patchwork of state-level and international laws, and no single data platform covers them all.

Speed of change makes old reports worthless. A market report published six months ago doesn't reflect the Schedule III rescheduling, the hemp redefinition timeline, or the latest state licensing changes. Roughly 32% of licensed cannabis businesses struggle to turn a profit. Understanding why requires current intelligence, not historical data snapshots. Cannabis businesses rely on real-time data about consumer behavior to optimize retail performance, and your investment thesis depends on the same real-time inputs.

Proof That Cannabis Research Works

Results in cannabis research are measured by decisions made and risk avoided.

Consider a PE firm evaluating a dual-licensed operator (medical and recreational cannabis) in Q2 2026. Without primary research, they might miss that the operator hasn't filed for DEA registration under the new Schedule III framework, exposing the business to continued 280E tax liability and potential federal enforcement, especially where medical use matters more than adult-use revenue. A single interview with a former compliance officer surfaces that risk before the LOI is signed.

Or consider a brand strategy team entering the edibles category. LeafLink's 2025 Wholesale Cannabis Pricing Guide, built on $5 billion of wholesale orders across 398,000 SKUs in 18 states, shows edibles and ingestibles pricing dropped approximately 9.85% year-over-year. Cartridges dropped approximately 12.04%. Flower was relatively stable at negative 3.04%. A cbd dominant segment can behave differently from THC-heavy categories in both margin profile and buyer mix. Edibles are among the fastest-growing sectors of the cannabis industry, but margin compression is real. An interview with a product development executive at a major MSO reveals whether the opportunity justifies the investment.

Cannabis added approximately $149 billion to the economy in 2025, and the industry supports 425,002 full-time equivalent jobs. Cannabis tax revenue reached nearly $25 billion by 2024, nearly double that of alcohol. These numbers confirm the market growth is real, and they also align with the medicinal benefits driving demand as a growing body of research continues to shape medical purchasing. Primary research tells you where the profit actually sits.

Who Cannabis Research Is For

PE/VC teams evaluating cannabis investments. You need due diligence that goes beyond market size projections. North America dominates the global cannabis market with over 83% market share in 2025 (North America accounted for 73.0% of global cannabis revenue in 2025 by another measure), but the competitive dynamics within that market vary dramatically by state and product category. Concentrates are set to witness exponential growth. Topicals are gaining traction in medical applications due to fewer barriers. Investors also need to separate chronic pain and pain management demand from purely adult-use demand when underwriting medical cannabis assets. You need expert interviews to understand which segments have real growth potential and which face margin compression.

Corporate development teams exploring cannabis. Whether you're assessing acquisition targets or evaluating market entry, you need intelligence on licensing requirements, distribution channel dynamics, and competitive positioning. An increasing number of Native American Tribes are establishing cannabis operations using their sovereign status, creating new competitive dynamics that public reports don't cover.

Strategy consultants building cannabis assessments. Your Fortune 500 client wants to understand the economic benefits of cannabis market entry. 64% of consumers use cannabis for relaxation purposes. 47% of Americans have tried cannabis at least once. More than 1 in 3 women over 21 consume cannabis. 25% of all cannabis sales now happen online through digital platforms. Some cohorts still associate cannabis with drug addiction, which affects messaging and policy risk. These consumer data points set the stage, but your client needs primary intelligence on regulatory risk, competitive threats, and operational viability.

Cannabis operators validating expansion. You're evaluating new state markets or product categories. Consumer demand is heavily driven by edibles, concentrates, and high-quality premium flower. Premium cannabis products command higher profit margins due to careful cultivation and rigorous testing. Some operators are also evaluating products positioned as a sleep aid. But the rising demand in a category doesn't mean your specific expansion plan will work. Interviews with operators already in that market tell you what the data can't.

Cannabis Research Pricing & Vendors

Traditional Expert Networks

GLG, AlphaSights, Third Bridge, and Guidepoint serve large hedge funds and consultancies. Their cannabis coverage exists but comes at enterprise pricing:

• Annual retainers starting at $150K+

• Minimum spend commitments per quarter

• Markup on expert honoraria (typical per-hour costs range $400 to $800+ for cannabis industry experts)

• Per-call expert fees generally range from $600 to $2,000 per hour depending on seniority

These networks have strong compliance infrastructure and broad expert databases. But if you're a mid-market fund or boutique consultant, the economics don't work. You're paying for access to thousands of sectors when you only need cannabis.

Boutique Research Services

FieldSignal and similar boutique providers offer a different model:

• Pay-per-use pricing with no annual retainer

• No minimum commitment or spend requirement

• Pass-through expert fees without markup on consultant honoraria

• Compliance infrastructure equivalent to established networks

• Expert vetting, interview guide development, and transcript delivery included

This model fits teams that need cannabis-specific primary research for a defined project without committing to an enterprise contract.

Secondary Data Providers

BDSA, Headset, New Frontier Data, and LeafLink provide cannabis market reports and data platforms, and teams often use them alongside secondary sources to estimate market size and compare how adjacent categories are defined:

Some datasets also break out THC dominant products separately from lower-THC or CBD-led categories, which can materially change category reads.

Syndicated reports cost $3,000 to $5,000 for global or regional coverage. Specialist single-market reports cost less but cover less. Subscription platforms run $10,000 to $50,000+ annually for multi-market, real-time access. The lag between data collection and report publication remains a structural limitation. Headset tracks over $1 billion in cannabis sales every month across millions of SKUs.

Alternative hemp-derived THC products have surged in popularity as mainstream revenue streams, and intoxicating hemp-derived products are becoming a major segment within the cannabis industry. The concentration of THC in herbal cannabis products continues to rise. But tracking these trends requires both secondary data and primary interviews with operators affected by the upcoming hemp redefinition.

Frequently Asked Questions

How quickly can I get cannabis market insights?

Expert interviews can be scheduled within 48 to 72 hours for urgent cannabis research needs. Transcripts and analysis are delivered within five business days of completed interviews. Secondary data from platforms like Headset or BDSA can produce usable results in one to two days if you already have a subscription.

Do I need cannabis industry expertise to conduct research?

No. Research vendors provide expert vetting, interview guide development, and compliance oversight. You bring the investment thesis or strategic question. The vendor connects you with the right cannabis industry insiders, including former regulators, compliance officers, and operators, and handles the logistics.

Is there legal risk in cannabis market research?

Reputable vendors maintain compliance equivalence with established expert networks. Interview protocols respect confidentiality and insider trading regulations. Experts are vetted for conflicts. NDAs are standard. The SAFE Banking Act aims to protect banking for cannabis businesses, but research compliance is separate from financial compliance. In Canada, that legal review matters even more because Health Canada oversees licensing and product compliance, and regulated studies are increasingly relevant when cannabis is evaluated as an alternative to some prescription medications. Work with a vendor that has documented protocols.

What about the global cannabis market?

Latin America's cannabis market is valued at over $440 million, driven by low production costs. Germany's Cannabis Act became effective in April 2024, though international demand is still split between medical and recreational use depending on jurisdiction. There is increasing legalization and growing demand across European markets, with the European Monitoring Centre tracking medicinal cannabis adoption. Some markets are also expanding around medical applications tied to multiple sclerosis and other qualifying conditions. Medical cannabis programs exist in dozens of countries. Primary research for international markets follows the same methodology but requires experts with jurisdiction-specific knowledge. North America dominated the global market in 2025, but cross border trade dynamics and global legalization trends are gaining momentum.

Which cannabis product categories should I focus on?

That depends on your investment thesis. In 2025, flower accounted for 42.5% of cannabis market share. Cannabis beverages are the fastest-growing product category at 14.6% CAGR. Edibles are among the fastest-growing cannabis product categories. 42% of edible consumers prefer a dosage of 10 mg or less, indicating a balanced THC, consumer-friendly segment. Concentrates are set for exponential growth. Product innovation in dried cannabis, cannabis flowers, and premium flower continues to drive market dynamics. The right expert interview can help you understand which categories offer real margin versus which face price compression. The US cannabis industry is projected to reach $47 billion in 2026.

Get Started with Cannabis Market Research

If you need cannabis market intelligence for an investment decision, market entry assessment, or competitive analysis, the next step is straightforward.

Tell us your research scope. We'll identify the right cannabis industry experts, handle compliance vetting, and deliver actionable insights without an annual retainer or minimum spend.

Legal cannabis is now available in 24 states for adult use. Medical marijuana use is legal in 42 states. The global cannabis market is transitioning rapidly, with legalization efforts, marijuana legalization, and policy reform addressing historic injustices related to cannabis prohibition all creating new market dynamics. Legalized cannabis has expanded unevenly across markets, so investors need to track both public health debates and commercial execution. There is a push for policy reform and increasing legalization across markets. Whether you're evaluating medical and recreational cannabis operators, assessing hemp-derived products under new federal rules, or validating market growth assumptions, primary research is how you get answers that secondary data can't provide.

Some end markets are shaped by whether consumers smoke marijuana or shift toward other formats, which affects demand modeling. Cannabis research doesn't require a six-figure budget. It requires the right experts and a vendor that doesn't mark up their time.

Get a quote for your research scope →

No long-term commitment. No hidden fees. Just the intelligence you need to make the decision.